Treatment Of Bipolar Illness Cl
, by Post,Robert M.
- ISBN: 9780393705379 | 0393705374
- Cover: Hardcover
- Copyright: 3/17/2008
Treatment of Bipolar Illness sets itself apart by focusing on the longitudinal course of manic-depressive illness and nuancesof clinical decision-making in its long-term treatment. Covering a broad range of drugs used alone and in complex combinationtherapy, Post and Leverich present the most comprehensive compendium to date of bipolar research, focusing onlong-term prevention of symptom relapse and addressing a range of critical clinical questions.
| Introduction | |
| Emil Kraepelin and the History of the Development of the Detailed Mood Chart | p. 3 |
| Phenomenology of Illness Course | |
| Acceleration in Cycle Frequency | p. 13 |
| Increasing Depressive Episode Frequency and Severity, and Baseline Dysfunction Between Episodes | p. 19 |
| Increasing Episode Duration and Shorter Well Intervals | p. 25 |
| An Unusual Case of Traumatic Stress Acutely Precipitating Both PTSD and Bipolar Illness | p. 31 |
| The Role of Psychosocial Stressors as Triggers for Episode Recurrence | p. 39 |
| Anniversary Reactions | p. 45 |
| The Development of Two Different Types of Treatment Resistance: Tolerance Versus Treatment Discontinuation and Loss of Efficacy Following Relapse | p. 51 |
| Pharmacology and Neurobiology of Bipolar Illness | |
| Fundamentals of Psychopharmacology Pertinent to Treatment of the Bipolar Disorders | p. 57 |
| Causes and Mechanisms of Bipolar Illness Onset and Progression | p. 77 |
| Response to Mood Stabilizers | |
| Lithium | |
| An Excellent Response to Lithium | p. 111 |
| Development of Treatment Resistance (via Tolerance) to the Prophylactic Effects of Lithium | p. 117 |
| Loss of Previous Responsiveness to Lithium Following Its Discontinuation and Subsequent Episode Recurrence | p. 123 |
| Carbamazepine | |
| Early Example of a Prophylactic Antimanic Response to Carbamazepine | p. 133 |
| Selective Response to Carbamazepine, but Not Valproate, Phenytoin, or Lithium | p. 139 |
| ECT-Sparing Effects of Carbamazepine Prophylaxis in a Patient With Recurrent Psychotic Depression: Predictors of Carbamazepine Response | p. 151 |
| Acute and Prophylactic Carbamazepine: Management of Side Effects | p. 157 |
| Excellent Response to Carbamazepine but Not Nimodipine: Possible Prediction From Baseline PET Scans and Other Biological Markers | p. 167 |
| Loss of Response to Carbamazepine and Lithium Combination Treatment via Tolerance: Reresponse After a Period Off Drug | p. 175 |
| Oxcarbazepine (Trileptal): A Close Structural Relative of Carbamazepine | p. 183 |
| Valproic Acid | |
| Prophylactic Response to Valproate in a Nonresponder to Lithium and Carbamazepine: Approaches to Side Effects | p. 191 |
| Prophylactic Antimanic Response to Valproate in a Lithium and Carbamazepine Nonresponder | p. 197 |
| Prophylactic Response to Valproate Augmentation of Lithium in Bipolar I Recurrent Psychotic Depressions | p. 203 |
| Gradual Loss of Responsiveness to the Long-Term Prophylactic Effects of Valproate: Tolerance and Reresponse | p. 209 |
| Lamotrigine | |
| Selective Response to Lamotrigine but Not Gabapentin or Placebo in Refractory Depression | p. 217 |
| Lamotrigine and Gabapentin Combination Therapy | p. 225 |
| Other Anticonvulsants | |
| Potential Antidepressant Response to Gabapentin in a Lamotrigine Partial Responder | p. 233 |
| Apparent Tolerance to Gabapentin Augmentation in an Ultrarapid-Cycling Patient | p. 237 |
| Prophylactic Response to Topiramate With Valproate in an Ultrarapid Cycler | p. 241 |
| Zonisamide: A Positive Side Effect of Weight Loss | p. 249 |
| Levetiracetam: Mysterious Mechanism of Action and Psychotropic Profile | p. 255 |
| Calcium Channel Blockers | |
| Unequivocal Response to Nimodipine: Cross-Responsivity to Isradipine, but Not to Verapamil | p. 263 |
| Ultra-Ultrarapid (Ultradian) Cycling Responding to the Combination of a Calcium Channel Antagonist and Carbamazepine | p. 271 |
| Antidepressants | |
| TCAs, MAOIs, and SSRIs | |
| Antidepressant-Associated Mania in a Bipolar I Patient With a Major Depressive Episode Breaking Through Lithium Prophylaxis | p. 283 |
| Rapid Cycling Associated With Antidepressants and Loss of Responsiveness to ECT: A Sample Consultation About Alternative Treatment Approaches | p. 291 |
| A Potential Liability of Unimodal Antidepressants in Bipolar Depression: Cycle Acceleration and Conversion to Ultradian Cycling | p. 299 |
| Antidepressant Discontinuation-Induced Refractoriness | p. 305 |
| Adjunctive Use of a Monoamine Oxidase Inhibitor to Renew Antidepressant Response to Carbamazepine in Bipolar II Depression | p. 313 |
| Bupropion and Venlafaxine | |
| Antidepressant Response to the Carbamazepine-Bupropion Combination, and to Each in Monotherapy | p. 321 |
| Antidepressant Response to Venlafaxine: Switch Rates, Mechanisms of Action, and Other Augmenting Strategies | p. 329 |
| Benzodiazepines | |
| Adjunctive High-Potency Benzodiazepines for Breakthrough Anxiety and Insomnia of Depression and Mania: Clonazepam and Lorazepam | p. 339 |
| Kindling of Cocaine-Related Panic Attacks: Response to Carbamazepine and Alprazolam | p. 343 |
| Paradoxical Exacerbation of Mood Lability by Clonazepam | p. 351 |
| Antipsychotics | |
| Typical Antipsychotics | |
| The Role of the Older Typical Antipsychotic Drugs in Bipolar Illness: A Case of Rapid Antimanic Response, but Much Slower Resolution of Psychosis | p. 359 |
| Atypical Antipsychotics | |
| Acute Antimanic Response to Olanzapine in a Patient With a Recurrent Psychotic Depression: Approaches to Weight Gain on Atypical Antipsychotics and Related Drugs | p. 369 |
| Response to Clozapine in an Olanzapine Nonresponder: Comment on Informed Consent | p. 379 |
| Atypical Antipsychotics Quetiapine, Risperidone, and Ziprasidone in Bipolar Illness | p. 385 |
| Aripiprazole: A Dopamine D[subscript 1], D[subscript 2], D[subscript 3] and Serotonin 5-HT[subscript 1A] Receptor Partial Agonist FDA Approved for Acute and Continuation Treatment of Mania | |
| Complex Combination Therapy | p. 393 |
| Response to the Combination of Carbamazepine and Valproate in the Absence of Response to Either Drug in Monotherapy and a Comment on Sleep Deprivation | p. 401 |
| Long-Term Remission Achieved With Complex Combination Therapy (Polypharmacy) | p. 407 |
| Thyroid Augmentation of Triple Mood Stabilizers Therapy | p. 415 |
| Complex Regimen Required to Stabilize a Patient With Antidepressant-Induced Cycling | p. 423 |
| Stabilization of Ultrarapid Cycling With Highly Complex Combination Therapy: Rationales | p. 429 |
| Complex Combination Therapy for the Reestablishment of Euthymia in a Bipolar II Patient | p. 435 |
| The Addition of Clozapine and an Antidepressant to Lamotrigine and Valproate in the Treatment of Ultrarapid Cycling | p. 441 |
| Electroconvulsive Therapy | |
| Role of Electroconvulsive Therapy in Acute Depression and Long-Term Prophylaxis of Bipolar Illness: Preliminary Risk-to-Benefit Analysis | p. 449 |
| Other Somatic Treatments | |
| Repeated Response to 20-Hz but Not to 1-Hz Repetitive Transcranial Magnetic Stimulation | p. 463 |
| Vagus Nerve Stimulation in the Treatment of Bipolar Depression | p. 471 |
| Sleep Deprivation: A Useful Facilitator of the Switch Out of Depression | p. 477 |
| Dietary and Other Supplements | |
| Omega-3 Fatty Acids in Depression Prophylaxis? | p. 485 |
| Acute Antidepressant Response and Tolerance to Thyrotropin-Releasing Hormone (TRH) | p. 493 |
| Overcoming Repeated Tolerance Development: Use of More Treatments in Combination, More Adjunctive Strategies, and a Question of the Ultimate Role of TRH | p. 499 |
| Illness Complications and Comorbidity | |
| Alcohol in Bipolar Illness | p. 509 |
| Cocaine and Related Psychomotor Stimulants in Bipolar Illness | p. 517 |
| Anger Attacks: A High Incidence in Childhood- and Adult-Onset Bipolar Illness | p. 525 |
| Remission in a Patient With Severe Bipolar Illness and Post-Traumatic Stress Disorder | p. 531 |
| Childhood Onset of Bipolar Illness | |
| Affective Dysfunction From Ages 3 to 11 and Improvement at Age 12 After Sequential Clinical Trials: Background on Pediatric Psychopharmacology of Bipolar Disorder | p. 541 |
| Nimodipine Treatment of an Adolescent With Ultradian Cycling Bipolar Affective Illness: Some Practical Treatment Principles for Parents of Children With Bipolar Illness | p. 551 |
| Conclusion | |
| Getting Well and Staying Well: Guidelines for Patients and Families | p. 565 |
| Appendices | |
| Medication Names and Classes | p. 575 |
| Life Charting | p. 583 |
| Bipolarity Index of Suspicion (The Speer/Post BIS) | p. 603 |
| Refractory Depression Indexes | p. 605 |
| The Mood Disorder Questionnaire (MDQ) | p. 609 |
| MAOI Diet and Information | p. 611 |
| Organizations Offering Information and Support Resources | p. 615 |
| References | p. 617 |
| Index | p. 655 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
What is included with this book?
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Please wait while the item is added to your bag...
